

ORIGINAL ARTICLE

Distinct expression patterns of ER α and ER β in normal human mammary gland

V Speirs, G P Skliris, S E Burdall, P J Carder

J Clin Pathol 2002;55:371–374

See end of article for authors' affiliations

Correspondence to:
Dr V Speirs, Molecular
Medicine Unit, Clinical
Sciences Building, St
James's University Hospital,
Leeds LS9 7TF, UK;
v.speirs@leeds.ac.uk

Accepted for publication
27 November 2001

Aim: Two oestrogen receptors (ERs) have been identified to date—the “classic” ER α and the more recently described ER β . Although much is known about ER α at the mRNA and protein levels, our knowledge of the expression and distribution of ER β protein is much more limited. The aim of this study was to compare the cellular distribution of ER α and ER β in normal human mammary gland.

Methods: Formalin fixed, paraffin wax embedded material was obtained from reduction mammoplasty specimens, normal tissue adjacent to breast tumour, or fibroadenoma. Sections were immunohistochemically stained for ER α , ER β , and the progesterone receptor. The staining pattern for each antibody was evaluated and compared.

Results: ER α was restricted to the cell nuclei of epithelial cells lining ducts and lobules. Although ER β was also seen in these cells, additional strong staining was detected specifically in the cell nuclei of myoepithelial cells. Occasional staining was seen in surrounding stromal and endothelial cell nuclei and in lymphocytes.

Conclusions: ER subtypes have distinct distribution patterns in the normal mammary gland. The widespread distribution of ER β suggests that it may be the dominant ER in the mammary gland where it may be acting as a natural suppressor.

Towards the end of the last century, a second oestrogen receptor (ER) was identified. To distinguish it from the original receptor, now re-christened ER α , the new receptor was called ER β .^{1,2} ERs are ligand activated transcription factors, which mediate the effect of oestrogens in steroid target tissues. The genes encoding the two types of receptor are located on different chromosomes: ER β has been mapped to chromosome 14q22–24,³ whereas ER α is located on chromosome 6q25.1.⁴ Although they are the product of independent genes, they share homology at the DNA and ligand binding domains (96% and 58%, respectively). Both receptor subtypes bind oestrogens with a similar affinity and activate the expression of reporter genes containing oestrogen response elements in an oestrogen dependent manner.⁵

Oestrogens are necessary for the development and maturation of the mammary gland. However, immunohistochemical analysis of breast tissue from premenopausal women has estimated that less than 20% of luminal epithelial cells express ER α .^{6–8} Curiously, double immunolabelling experiments in both human and murine mammary gland have shown that cells that are immunopositive for ER α very rarely undergo proliferation, as determined by the lack of expression of the cell cycle associated antigens Ki-67 and proliferative cell nuclear antigen, or failure to incorporate ³H-thymidine.^{7–9} It has been hypothesised that the lack of proliferation seen in ER α positive cells may indicate a hierarchical organisation, whereby the proliferation of ER α negative cells is under the control of paracrine factors released from their ER α positive counterparts.⁸ However, the discovery of ER β opens up the possibility that cells originally considered ER α negative may in fact be expressing ER β . The presence of ER β has been demonstrated by reverse transcription polymerase reaction (RT-PCR) in the normal mammary gland, where it was frequently detected.^{10,11} This was in contrast to breast tumours where the expression of ER β is usually seen only in combination with ER α .^{10,12} However, RT-PCR is limited because it cannot provide information on cellular distribution patterns. Therefore, the aim of our study was to evaluate the pattern of expression and distribution of both ER subtypes in archival, paraffin wax

embedded, normal human mammary gland and to correlate this with the expression of the ER regulated progesterone receptor (PR).

“Both receptor subtypes bind oestrogens with a similar affinity and activate the expression of reporter genes containing oestrogen response elements in an oestrogen dependent manner”

METHODS

With approval from the local ethics committee, archival paraffin wax embedded material from normal breast adjacent to tumours (n = 65), reduction mammoplasty material (n = 30), or fibroadenoma (n = 2) was obtained. Serial sections (4–5 μ m thick) were mounted on to superfrost plus slides (BDH, Poole, Dorset, UK), dewaxed in xylene, and rehydrated through graded alcohols. To unmask antigenic sites, slides were immersed in 1mM citrate buffer, pH 6, and microwaved at full power (600 W) for 27 minutes for ER α and ER β , and 10 minutes for PR. After cooling, sections were then incubated with the relevant monoclonal antibodies. For ER α , the monoclonal antibody 1D5 (Dako, High Wycombe, UK) was applied at a dilution of 1/50 for one hour at room temperature. For ER β , the monoclonal antibody 14C8 (Abcam, Cambridge, UK) was applied at a dilution of 5 μ g/ml overnight at 4°C. Validation of this antibody has previously been published by our group.¹² The antibody was affinity purified and raised by immunising mice with a recombinant protein encoding 1–153 amino acids of the human ER β sequence. According to the manufacturers, there is no crossreactivity of 14C8 with human ER α or ID5 with human ER β . For PR, the monoclonal antibody PgR636 (Dako) was used at a 1/50 dilution for one hour at room temperature. After incubation with the

Abbreviations: ER, oestrogen receptor; PR, progesterone receptor; RT-PCR, reverse transcription polymerase reaction




Figure 1 (A) Expression of oestrogen receptor α (ER α) in normal mammary gland. Staining is restricted to the epithelial cells lining the breast ducts (arrows). (B) Serial section of (A) but stained with a monoclonal antibody directed against ER β . In addition to staining the ductal epithelium (D), ER β immunoreactivity is also seen in myoepithelial cells (M) and scattered periductal stromal fibroblasts (F). (C) Breast lobule showing ER β immunoreactivity in epithelial cells (E), intralobular fibroblasts (F), and in endothelial cells lining a blood vessel (V). (D) Progesterone receptor immunoreactivity in the nuclei of normal breast epithelium (arrow).

appropriate biotinylated secondary antibody (Dako anti-mouse; 1/200 dilution) for 30 minutes at room temperature, then incubation with streptavidin ABC kit (Dako), the ER and PR proteins were visualised with 3,3'-diaminobenzidine (Vector, Peterborough, UK). Negative controls included the omission of the primary antibody or incubation with the

appropriate blocking peptide. Sections were lightly counterstained with haematoxylin, dehydrated, and coverslipped. Slides were scored using a system involving the assessment of staining intensity and percentage positivity, which generated a numerical score of 0 to 8.¹³ A score of > 2 was classified as positive. Staining was scored independently by two authors

(GPS, PJC). Representative images were captured using a Nikon light microscope attached to a computer equipped with Lucia software (version 4.51).

RESULTS

Using serial sections, the expression and distribution of ER α and ER β were analysed and compared. In accordance with previous reports, ER α was restricted to the cell nuclei of luminal epithelial cells lining ducts and lobules (fig 1A). However, a much more widespread pattern of staining was seen with ER β (fig 1B). As with ER α , this receptor was also seen in the nuclei of the same epithelial cells lining breast ducts and lobules (fig 1B). However, additional strong staining was detected specifically in the cell nuclei of myoepithelial cells (fig 1B). Weak to moderate staining was seen in some intralobular stromal cell nuclei, in nuclei of endothelial cells lining blood vessels (fig 1C), and in lymphocytes. Whereas the expression of ER α and ER β tended to be uniform across a given section, a more patchy distribution pattern was seen for PR, with weak to moderate staining. PR was specifically localised to epithelial cells (fig 1D), and although the coexpression of PR and ER α and ER β was seen in the same tissue section, it was not always in the same cells.

In general, ER β immunoreactivity was much stronger than that of ER α , and the staining pattern was identical in breast reduction specimens and in normal tissue adjacent to tumours. In addition, the staining pattern and intensity for ER β did not appear to be affected by patient age. In all cases, specific staining was abolished in negative controls.

DISCUSSION

We have shown the differential expression of the two ER subtypes—ER α and ER β —in normal human mammary gland, with much more widespread expression of ER β compared with ER α .

The distribution patterns of each receptor were distinct. Whereas ER α was restricted to the cell nuclei of epithelial cells, a striking observation was the strong expression of ER β in the nuclei of myoepithelial cells. The presence of ER β in these cells may provide clues as to the function of this receptor subtype in the mammary gland. The myoepithelium forms a natural barrier separating proliferating epithelial cells from the basement membrane and the underlying stroma. Myoepithelial cells rarely undergo transformation and there is experimental evidence that they may act as natural tumour suppressors.¹⁴ In the mammary gland, loss of ER β in the transition from benign lesion to carcinoma *in situ* has recently been reported,^{15, 16} prompting the proposal that ER β may have a role as a tumour suppressor.¹⁵ Strong, specific expression of ER β in the myoepithelium may strengthen this hypothesis, where it may be fulfilling a protective function. Further evidence in support of this is provided by Taylor and Al-Azzawi,¹⁷ who described increased ER β immunoreactivity in the glands of normal resting breast tissue compared with proliferative breast tissue.

In gene knockout studies, the presence of ER α but not ER β is necessary for the development of the mouse mammary gland.¹⁸ Therefore, ER β may be acting as an antagonist of ER α and removing its antagonistic effect may be akin to “removing a brake”. Thus, by removing ER β the suppressive effect of the receptor is lost. Alternatively, the putative suppressive effects of ER β may be dictated by the downstream signalling pathway. Both ER subtypes can signal via classic oestrogen response elements or via AP-1 enhancers.¹⁹ The downstream effects of signalling through AP-1 are both receptor and ligand specific. Whereas ER α –17 β -estradiol complexes activate gene transcription, the reverse is true for ER β –17 β -estradiol complexes.²⁰ Thus, if signalling is mediated through AP-1, an inhibitory effect of ER β might be expected.

Take home messages

- Oestrogen receptor α (ER α) expression was restricted to the cell nuclei of epithelial cells lining ducts and lobules
- ER β was also expressed in these cells but additional strong staining was seen in the cell nuclei of myoepithelial cells and occasionally in surrounding stromal and endothelial cell nuclei and in lymphocytes
- Thus, ER subtypes have distinct distribution patterns in the normal mammary gland
- The widespread distribution of ER β suggests that it may be the dominant ER in the mammary gland, where it may be acting as a natural suppressor

ER β was also observed in lymphocytes, stromal cells, and endothelial cells. It has long been known that oestrogens have important effects on the immune system and to this end ER β expression in lymphocytes has previously been reported.³ We and others have reported stromal immunoreactivity for ER β in the mammary gland,^{11, 16, 17} and this has also been noted in colon²¹ and prostate.²² In the endothelium, where it plays a role in vascular remodelling,^{23, 24} ER β is believed to be the dominant receptor subtype. Despite these observations, the functional importance of ER β in non-epithelial cells is unclear, although it may be fulfilling a paracrine role. Future studies are required to investigate this question.

“Myoepithelial cells rarely undergo transformation and there is experimental evidence that they may act as natural tumour suppressors”

In the mouse mammary gland, ER β is expressed by 60–70% of epithelial cells, irrespective of the stage of breast development.⁹ In our study, we did not attempt to correlate ER β expression with the developmental or hormonal state of the mammary gland: all reduction mammoplasty and fibroadenoma samples were from premenopausal patients whose menstrual status was unknown, whereas the normal breast samples adjacent to tumours were predominantly from postmenopausal patients. However, it would be interesting to determine whether the expression of this receptor changes according to the hormonal milieu of the breast. Although age related changes in the expression of ER α have been reported in normal mammary gland, where the proportion of ER α positive cells increases with age,²⁵ we saw no such changes in either the proportion or degree of expression of ER β when glands from premenopausal and postmenopausal women were compared.

Although it is well established that ER α is regulated by PR, there have been conflicting reports regarding the relation between ER β and PR. In the endometrium, PR significantly correlated with ER α , but not with ER β .²⁶ A study of human prostate revealed a significant association between PR and both ER α and ER β , where it was concluded that both ER subtypes could induce PR expression.²⁷ In our present study, the analysis of serial sections revealed that although ER β and PR expression could be seen in the same tissue sections, it was not always in the same cells. Thus, it seems likely that there is an association between ER β and PR in the mammary gland.

In conclusion, ER subtypes have distinct distribution patterns in the normal mammary gland. The widespread distribution of ER β suggests it may be the dominant ER in the mammary gland, where we propose it may be acting as a natural suppressor of oestrogen activity.

ACKNOWLEDGEMENTS

This work was supported by grants from Yorkshire Cancer Research and the Northern and Yorkshire NHS Executive.

.....
Authors' affiliations

V Speirs, G P Skliris, S E Burdall, Molecular Medicine Unit, University of Leeds, St James's University Hospital, Leeds LS9 7TF, UK

P J Carder, Histopathology Department, St James's University Hospital

REFERENCES

- 1 **Kuiper GG**, Enmark E, Peltö-Huikko M, *et al.* Cloning of a novel receptor expressed in rat prostate and ovary. *Proc Natl Acad Sci U S A* 1996;**93**:5925–30.
- 2 **Mosselman S**, Polman J, Dijkema R. ER- β : identification and characterisation of a novel human oestrogen receptor. *FEBS Lett* 1996;**392**:49–53.
- 3 **Enmark E**, Peltö-Huikko M, Grandien K, *et al.* Human oestrogen receptor β -gene structure, chromosomal localisation and expression pattern. *J Clin Endocrinol Metab* 1997;**82**:4258–65.
- 4 **Menasce LP**, White GR, Harrison CJ, *et al.* Localisation of the oestrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. *Genomics* 1993;**17**:263–5.
- 5 **Kuiper GGJM**, Carlsson B, Grandien K, *et al.* Comparison of the ligand binding specificity and transcript tissue distribution of oestrogen receptors α and β . *Endocrinology* 1997;**138**:863–70.
- 6 **Jacquemier JD**, Hasson J, Tarrente M, *et al.* Distribution of oestrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages. Immunohistochemical study of 107 cases. *Breast Cancer Res Treat* 1990;**15**:109–17.
- 7 **Russo J**, Ao X, Grill C, *et al.* Pattern of distribution of cells positive for oestrogen receptor α and progesterone receptor in relation to proliferating cells in the mammary gland. *Breast Cancer Res Treat* 1999;**53**:217–27.
- 8 **Clarke RB**, Howell A, Potten CS, *et al.* Dissociation between steroid receptor expression and cell proliferation in the human breast. *Cancer Res* 1997;**57**:4987–91.
- 9 **Saji S**, Jensen EV, Nilsson S, *et al.* Oestrogen receptors α and β in the rodent mammary gland. *Proc Natl Acad Sci U S A* 2000;**97**:337–42.
- 10 **Speirs V**, Parkes AT, Kerin MJ, *et al.* Co-expression of oestrogen receptor- α and - β : poor prognostic factors in human breast cancer? *Cancer Res* 1999;**59**:525–8.
- 11 **Speirs V**, Adams IP, Walton DS, *et al.* Identification of wild type and exon 5 deletion variants of oestrogen receptor β in normal human mammary gland. *J Clin Endocrinol Metab* 2000;**85**:1601–5.
- 12 **Skliris GP**, Carder PJ, Lansdown MRJ, *et al.* Immunohistochemical detection of ER β in breast cancer: towards more detailed receptor profiling? *Br J Cancer* 2001;**84**:1095–8.
- 13 **Allred DC**, Harvey MJ, Berardo M, *et al.* Prognostic and predictive factors in breast cancer by immunohistochemical analysis. *Mod Pathol* 1998;**2**:155–68.
- 14 **Sternlicht MD**, Kedeshian P, Shao Z-M, *et al.* The human myoepithelial cell is a natural tumour suppressor. *Clin Cancer Res* 1997;**3**:1949–58.
- 15 **Iwao K**, Miyoshi Y, Egawa C, *et al.* Quantitative analysis of oestrogen receptor- β mRNA and its variants in human breast cancers. *Int J Cancer* 2000;**88**:733–6.
- 16 **Roger P**, Sahla ME, Makela S, *et al.* Decreased expression of oestrogen receptor β protein in proliferative preinvasive mammary tumours. *Cancer Res* 2001;**61**:2537–41.
- 17 **Taylor AH**, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. *J Mol Endocrinol* 2000;**24**:145–55.
- 18 **Krege JH**, Hodgin JB, Couse JF, *et al.* Generation and reproductive phenotypes of mice lacking oestrogen receptor β . *Proc Natl Acad Sci U S A* 1998;**95**:15677–82.
- 19 **Gaub M-P**, Bellard M, Scheuer I, *et al.* Activation of the ovalbumin gene by the oestrogen receptor involves the fos-jun complex. *Cell* 1990;**63**:1267–76.
- 20 **Paech K**, Webb P, Kuiper GGJM, *et al.* Differential ligand activation of oestrogen receptors ER α and ER β at AP-1 sites. *Science* 1997;**277**:1508–10.
- 21 **Witte D**, Chirala M, Younes A, *et al.* Estrogen receptor β is expressed in human colorectal adenocarcinoma. *Hum Pathol* 2001;**32**:940–4.
- 22 **Horvath LG**, Henshall SM, Lee C-S, *et al.* Frequent loss of estrogen receptor β expression in prostate cancer. *Cancer Res* 2001;**61**:5331–5.
- 23 **Critchley HO**, Brenner RM, Henderson TA, *et al.* Oestrogen receptor β , but not oestrogen receptor α , is present in the vascular endothelium of the human and non-human primate endometrium. *J Clin Endocrinol Metab* 2001;**86**:1370–8.
- 24 **Lindner V**, Kim SK, Karas RH, *et al.* Increased expression of oestrogen receptor-beta mRNA in male blood vessels after vascular injury. *Circ Res* 1998;**83**:224–9.
- 25 **Shoker BS**, Jarvis C, Clarke RB, *et al.* Oestrogen receptor-positive proliferating cells in the normal and pre-cancerous breast. *Am J Pathol* 1999;**155**:1811–15.
- 26 **Saegusa M**, Okayasu I. Changes in expression of oestrogen receptors alpha and beta in relation to progesterone receptor and pS2 status in normal and malignant endometrium. *Jpn J Cancer Res* 2000;**91**:510–18.
- 27 **Latil A**, Bieche I, Vidaud D, *et al.* Evaluation of androgen, oestrogen (ER α and ER β) and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. *Cancer Res* 2001;**61**:1919–26.